New protein engineering-based tools and technologies for characterizing cell surface proteolysis in cancer cells for novel neo-epitope biomarkers and drug targets
基于新蛋白质工程的工具和技术,用于表征癌细胞中的细胞表面蛋白水解,以获得新型新表位生物标志物和药物靶点
基本信息
- 批准号:10582604
- 负责人:
- 金额:$ 35.61万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-04-01 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalAntibodiesAntibody AffinityBacteriophagesBindingBiological MarkersCRISPR interferenceCancer cell lineCell LineCell Surface ProteinsCell modelCell secretionCell surfaceCellsCoupledDataDiseaseDrug TargetingEngineeringEnvironmental Risk FactorEventExtracellular DomainExtracellular SpaceGenerationsHumanHypoxiaImmunooncologyKRAS2 geneKRASG12DLabelLibrariesLigaseMalignant NeoplasmsMalignant neoplasm of pancreasMalignant neoplasm of prostateMeasuresOncogenesOncogenicPancreatic Ductal AdenocarcinomaPancreatic ductPeptide HydrolasesPeptidesPhage DisplayProstate-Specific AntigenProtein EngineeringProteinsProteolysisProteomeProteomicsReagentReceptor ActivationSiteSolid NeoplasmSpecificitySurfaceTechnologyTherapeuticTissue SampleUrokinasecancer biomarkerscancer celldesignexperimental studyextracellularinhibitorinsightknock-downmalignant breast neoplasmmutantneoantigensnew technologynovelpancreatic cancer modelpancreatic cell linepotential biomarkerreceptorsmall molecule inhibitorsubtiligasetooltumortumor microenvironmenttwo-dimensional
项目摘要
Project Summary
Extracellular proteolysis is a hallmark of cancer. Proteolysis has major functional consequences for
remodeling cell surface proteins and matrix including receptor activation and shedding of receptor
extracellular domains. Of the more than 600 human proteases, over half are on the cell surface or
secreted reflecting their significance for processing the extracellular space. Yet we understand very
little about the targets for cell surface proteolysis (CSP), the proteases responsible, and resulting neo-
cleaved products that could serve as new biomarkers or drug targets.
What has been missing are robust technologies for unbiased identification of the CSP targets,
their specific sites of cleavage, the proteases responsible for promoting disease, and the generation of
neo-epitope specific antibodies. My group has engineered a novel peptide ligase, called subtiligase,
and shown it robustly labels sites of proteolysis of soluble proteins. Our preliminary data show that this
powerful tool can be used to determine the targets and precise sites of cleavage for CSP. We propose
this novel CSP technology can be used to determine CSP signatures in cancer. We will initially focus
on KRAS, the most dominant oncogene, especially in pancreatic cancer. We will determine KRAS-
induced proteolysis in isogenic pancreatic cell lines, with and without mutant KRAS, grown in hypoxic
and normoxic conditions in the context of two- and three-dimensional culture. We will identify the
surface proteases up-regulated using cell surface capture (CSC) proteomics and confirm their activities
using CRISPRi or small molecule inhibitors. We will characterize their specificities using new substrate
phage technology coupled with NGS and match these to neo-epitopes we discover. Lastly, we will
further exploit differential antibody phage display selection technology, and generate antibodies specific
to the cleaved forms of various identified targets, including CDCP1. We will develop important
technologies for new neo-epitope biomarkers and potential immune-oncology reagents for the
characterization of these important cleavage events.
Impact: Our studies will provide robust protein engineering-based technologies for unbiased
insights into how CSP remodels cells, the proteases responsible, and actionable oncogene specific
neo-epitopes to generate antibodies as potential biomarkers and therapeutics. We believe these
approaches will be generally applicable to characterizing proteolysis in other solid tumor cancers.
项目摘要
细胞外蛋白水解是癌症的标志。蛋白质水解具有主要的功能性后果,
重塑细胞表面蛋白和基质,包括受体活化和受体脱落
胞外结构域。在超过600种人类蛋白酶中,超过一半位于细胞表面或
分泌反映其对处理细胞外空间的重要性。但我们非常理解
关于细胞表面蛋白水解(CSP)的靶点,负责的蛋白酶,以及由此产生的新-
裂解产物可以作为新的生物标志物或药物靶点。
缺少的是用于无偏见地识别CSP目标的强大技术,
它们的特定切割位点,负责促进疾病的蛋白酶,以及
新表位特异性抗体。我的团队已经设计了一种新的肽连接酶,叫做枯草杆菌连接酶,
并显示它能有力地标记可溶性蛋白质的蛋白水解位点。我们的初步数据显示,
这是一个强有力的工具,可用于确定CSP的靶点和精确切割位点。我们提出
这种新的CSP技术可用于确定癌症中的CSP特征。我们将首先关注
KRAS是最主要的致癌基因,尤其是在胰腺癌中。我们将决定KRAS-
在低氧环境中生长的具有和不具有突变KRAS的同基因胰腺细胞系中诱导蛋白水解
和常氧条件下的二维和三维培养。我们将确定
使用细胞表面捕获(CSC)蛋白质组学上调表面蛋白酶,并确认其活性
使用CRISPRi或小分子抑制剂。我们将使用新的底物来表征它们的特异性
噬菌体技术与NGS结合,并将这些与我们发现的新表位相匹配。最后,我们将
进一步利用差异抗体噬菌体展示筛选技术,
包括CDCP 1在内的各种已鉴定靶点的切割形式。我们将发展重要的
新的新表位生物标志物和潜在的免疫肿瘤学试剂的技术,
这些重要的裂解事件的表征。
影响:我们的研究将提供强大的基于蛋白质工程的技术,
深入了解CSP如何重塑细胞,负责的蛋白酶和可操作的癌基因特异性
新表位以产生作为潜在生物标志物和治疗剂的抗体。我们相信这些
这些方法通常可用于表征其它实体瘤癌症中的蛋白水解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JAMES A WELLS其他文献
JAMES A WELLS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JAMES A WELLS', 18)}}的其他基金
New protein engineering-based tools and technologies for characterizing cell surface proteolysis in cancer cells for novel neo-epitope biomarkers and drug targets
基于新蛋白质工程的工具和技术,用于表征癌细胞中的细胞表面蛋白水解,以获得新型新表位生物标志物和药物靶点
- 批准号:
10371980 - 财政年份:2020
- 资助金额:
$ 35.61万 - 项目类别:
Surfaceomic technologies and antibodies to probe cell surface proteomes and their interactomes at unprecedented small scale and high-resolution
表面组学技术和抗体以前所未有的小规模和高分辨率探测细胞表面蛋白质组及其相互作用组
- 批准号:
10552328 - 财政年份:2017
- 资助金额:
$ 35.61万 - 项目类别:
Discovering how oncogenes remodel the surfaceome of cells
发现癌基因如何重塑细胞表面组
- 批准号:
10212408 - 财政年份:2017
- 资助金额:
$ 35.61万 - 项目类别:
Affinity-directed tagging of protein binding partners in signaling
信号传导中蛋白质结合伴侣的亲和定向标记
- 批准号:
8628677 - 财政年份:2014
- 资助金额:
$ 35.61万 - 项目类别:
Renewable Antibodies for Post Translational Modifications and Protease Activatio
用于翻译后修饰和蛋白酶激活的可再生抗体
- 批准号:
8702418 - 财政年份:2014
- 资助金额:
$ 35.61万 - 项目类别:
Generation of recombinant thiopeptides to target antimicrobial-resistant bacteria
生成重组硫肽以靶向抗菌素耐药细菌
- 批准号:
8798574 - 财政年份:2014
- 资助金额:
$ 35.61万 - 项目类别:
Affinity-directed tagging of protein binding partners in signaling
信号传导中蛋白质结合伴侣的亲和定向标记
- 批准号:
8871699 - 财政年份:2014
- 资助金额:
$ 35.61万 - 项目类别:
Affinity-directed tagging of protein binding partners in signaling
信号传导中蛋白质结合伴侣的亲和定向标记
- 批准号:
9065515 - 财政年份:2014
- 资助金额:
$ 35.61万 - 项目类别:
Automated System for High-Throughput In Vitro Selection of Recombinant Antibodies
用于重组抗体高通量体外选择的自动化系统
- 批准号:
8247377 - 财政年份:2012
- 资助金额:
$ 35.61万 - 项目类别:
IDENTIFICATION OF PROTEOLYSIS-DEPENDENT EXECUTIONER CASPASE PROTEIN COMPLEXES
蛋白水解依赖性执行器 Caspase 蛋白复合物的鉴定
- 批准号:
8363836 - 财政年份:2011
- 资助金额:
$ 35.61万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 35.61万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 35.61万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 35.61万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 35.61万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 35.61万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 35.61万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 35.61万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 35.61万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 35.61万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 35.61万 - 项目类别: